Oral Ibrexafungerp (SCY-078) vs Standard-of-Care Following IV Echinocandin in the Treatment of Invasive Candidiasis

Exclusion Criteria

• •Patient with Candida endocarditis, osteomyelitis, meningitis, or chronic disseminated candidiasis or evidence of endophthalmitis.
• •Patient has failed treatment with an echinocandin for this episode of invasive candidiasis.
• •Infection limited to the oropharynx, esophagus, urogenital system, or skin, or sputum/bronchoalveolar lavage culture.
• •Participation in a clinical study with other investigational drug(s) within 30 days prior to study entry or during this study.